PMID- 34367306
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220425
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Novel Compound Q-1 Alleviates Type II Collagen-Induced Arthritis in Rats through 
      the NF-kappaB Pathway.
PG  - 6627290
LID - 10.1155/2021/6627290 [doi]
LID - 6627290
AB  - BACKGROUND: Q-1 is a novel compound extracted from the Miao medicine Tiekuaizi. 
      Although Q-1 is known to be a coumarin derivative, its structure has not been 
      deposited in the ACX library. Our previous study showed that Q-1 inhibits the 
      activity of inflammatory cells. This study explores the efficacy of Q-1 in 
      regulating rheumatoid arthritis (RA). The findings show that Q-1 acts through the 
      NF-kappaB signaling pathway. METHODS: The effects of Q-1 were explored using a bovine 
      type II collagen-induced arthritis (CIA) rat model. The CIA rats were 
      intragastrically administered with high (30 mg.kg(-1)) or low (15 mg.kg(-1)) 
      doses of Q-1. The control group was administered with an equal volume of drinking 
      water, while the positive control group was administered with Tripterygium 
      glycoside (9.45 mg.kg(-1)) for 28 consecutive days. The arthritis indices and 
      ankle joint swelling rates were determined. The levels of IL-1beta, IL-6, monocyte 
      chemoattractant protein-1 (MCP-1) in serum and sialic acid (SA) in liver 
      homogenate were determined by enzyme-linked immunosorbent assay (ELISA). The 
      pathological features of the ankle joint were analyzed by hematoxylin and eosin 
      (HE) staining. The IkappaB, P-IkappaB, P65, and P-P65 protein levels in synovial tissue 
      were assayed by western blotting. RESULTS: The arthritis index, ankle joint 
      swelling rate, IL-1beta, IL-6, and MCP-1 levels in serum, SA level in liver tissue, 
      and IkappaB, P-IkappaB, P65, and P-P65 protein levels in synovial tissues were 
      significantly higher (P < 0.01) in the CIA model compared to the control group. 
      RA was successfully replicated by the CIA model, as shown by the joint swelling 
      results and histopathological sections of the ankle. Notably, all the above 
      indicators decreased significantly (P < 0.01) after treatment with Q-1 compared 
      to the model. In addition, animals treated with Q-1 showed lower inflammation in 
      the ankle joints than the model rats. CONCLUSION: The findings indicate that Q-1 
      effectively inhibited RA in rats by downregulating IkappaB, P-IkappaB, P65, and P-P65, 
      inhibiting the excessive release of inflammatory factors, and inhibiting the 
      overactivation of the NF-kappaB signaling pathway.
CI  - Copyright (c) 2021 Ting Xu et al.
FAU - Xu, Ting
AU  - Xu T
AUID- ORCID: 0000-0002-6797-0672
AD  - Guizhou University of Traditional Chinese Medicine, Guiyang, China.
AD  - Key Laboratory of General Higher Education Institutions in Guizhou Province, 
      Guiyang, China.
FAU - Guo, Jia-Chen
AU  - Guo JC
AD  - Guizhou University of Traditional Chinese Medicine, Guiyang, China.
AD  - Chengdu University of Traditional Chinese Medicine, Chengdu, China.
FAU - Wu, Sha-Sha
AU  - Wu SS
AD  - Guizhou University of Traditional Chinese Medicine, Guiyang, China.
AD  - Key Laboratory of General Higher Education Institutions in Guizhou Province, 
      Guiyang, China.
FAU - Wang, Yan
AU  - Wang Y
AD  - Guizhou University of Traditional Chinese Medicine, Guiyang, China.
AD  - Key Laboratory of General Higher Education Institutions in Guizhou Province, 
      Guiyang, China.
FAU - Liu, Xiao-Long
AU  - Liu XL
AD  - Guizhou University of Traditional Chinese Medicine, Guiyang, China.
AD  - Key Laboratory of General Higher Education Institutions in Guizhou Province, 
      Guiyang, China.
FAU - Qian, Hai-Bing
AU  - Qian HB
AUID- ORCID: 0000-0001-7687-6218
AD  - Guizhou University of Traditional Chinese Medicine, Guiyang, China.
AD  - Key Laboratory of General Higher Education Institutions in Guizhou Province, 
      Guiyang, China.
LA  - eng
PT  - Journal Article
DEP - 20210630
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8339345
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2021/08/10 06:00
MHDA- 2021/08/10 06:01
PMCR- 2021/06/30
CRDT- 2021/08/09 06:31
PHST- 2020/11/22 00:00 [received]
PHST- 2021/05/17 00:00 [revised]
PHST- 2021/06/15 00:00 [accepted]
PHST- 2021/08/09 06:31 [entrez]
PHST- 2021/08/10 06:00 [pubmed]
PHST- 2021/08/10 06:01 [medline]
PHST- 2021/06/30 00:00 [pmc-release]
AID - 10.1155/2021/6627290 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Jun 30;2021:6627290. doi: 
      10.1155/2021/6627290. eCollection 2021.